IL137999A0 - Vaccine compositions - Google Patents
Vaccine compositionsInfo
- Publication number
- IL137999A0 IL137999A0 IL13799999A IL13799999A IL137999A0 IL 137999 A0 IL137999 A0 IL 137999A0 IL 13799999 A IL13799999 A IL 13799999A IL 13799999 A IL13799999 A IL 13799999A IL 137999 A0 IL137999 A0 IL 137999A0
- Authority
- IL
- Israel
- Prior art keywords
- vaccine compositions
- vaccine
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806456.1A GB9806456D0 (en) | 1998-03-25 | 1998-03-25 | Vaccine composition |
PCT/EP1999/001959 WO1999048525A1 (en) | 1998-03-25 | 1999-03-22 | Hib/dtpa vaccine composition and methods of preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL137999A0 true IL137999A0 (en) | 2001-10-31 |
Family
ID=10829286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13799999A IL137999A0 (en) | 1998-03-25 | 1999-03-22 | Vaccine compositions |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1066053B8 (xx) |
JP (1) | JP2002507581A (xx) |
KR (1) | KR20010034630A (xx) |
CN (1) | CN1295481A (xx) |
AR (1) | AR014762A1 (xx) |
AT (1) | ATE335509T1 (xx) |
AU (1) | AU735619B2 (xx) |
BR (1) | BR9909037A (xx) |
CA (1) | CA2325436A1 (xx) |
CO (1) | CO4820442A1 (xx) |
CZ (1) | CZ20003536A3 (xx) |
DE (1) | DE69932709T2 (xx) |
ES (1) | ES2270590T3 (xx) |
GB (1) | GB9806456D0 (xx) |
HU (1) | HUP0101323A1 (xx) |
IL (1) | IL137999A0 (xx) |
MY (1) | MY133780A (xx) |
NO (1) | NO20004758L (xx) |
NZ (1) | NZ506604A (xx) |
PL (1) | PL343065A1 (xx) |
TR (1) | TR200002737T2 (xx) |
WO (1) | WO1999048525A1 (xx) |
ZA (1) | ZA200004956B (xx) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020054884A1 (en) | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
DE69935606T9 (de) * | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
EP1004314A1 (fr) * | 1998-11-26 | 2000-05-31 | Pasteur Merieux MSD | Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée |
US20030180316A1 (en) * | 2000-06-29 | 2003-09-25 | Dominique Boutriau | Multivalent vaccine composition |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
KR100385711B1 (ko) * | 2000-07-05 | 2003-05-27 | 녹십자백신 주식회사 | 디프테리아, 파상풍 톡소이드와 백일해균 및b형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법 |
KR100401423B1 (ko) * | 2001-01-10 | 2003-10-17 | 주식회사 엘지생명과학 | 혼합 백신의 제조 방법 |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
EP1409013B1 (en) * | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
FR2828406B1 (fr) * | 2001-08-08 | 2005-06-24 | Aventis Pasteur | Composition vaccinale bivalente havi |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0223355D0 (en) * | 2002-10-08 | 2002-11-13 | Chiron Spa | Vaccine |
ES2649048T3 (es) | 2002-11-01 | 2018-01-09 | Glaxosmithkline Biologicals S.A. | Procedimiento de secado |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
MXPA05014171A (es) * | 2003-06-23 | 2007-02-21 | Sanofi Pasteur Inc | Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c. |
US7867715B2 (en) | 2003-08-05 | 2011-01-11 | Alk-Abello A/S | Method of evaluating the immunological activity of a vaccine |
WO2005074650A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
NZ564606A (en) | 2005-06-27 | 2010-10-29 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising atleast two N. meningitidis capsular polysaccharides conjugated through a linker protein |
EP1862176A1 (de) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
EP1862177A1 (de) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
GB0617602D0 (en) * | 2006-09-07 | 2006-10-18 | Glaxosmithkline Biolog Sa | Vaccine |
AU2007293672B2 (en) * | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
PE20100366A1 (es) | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
PT3246044T (pt) | 2010-08-23 | 2021-02-15 | Wyeth Llc | Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis |
NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
CN102198270B (zh) * | 2011-05-16 | 2012-06-27 | 大连汉信生物制药有限公司 | 一种含铝佐剂乙肝疫苗的制备方法 |
EP2822584A1 (en) * | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
NZ628449A (en) | 2012-03-09 | 2016-04-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
MY172181A (en) | 2013-03-08 | 2019-11-15 | Janssen Vaccines & Prevention Bv | Acellular pertussis vaccine |
EP4098276A1 (en) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
KR20170103009A (ko) | 2015-02-19 | 2017-09-12 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
CN118021947A (zh) | 2017-01-31 | 2024-05-14 | 辉瑞大药厂 | 脑膜炎奈瑟菌组合物及其使用方法 |
CN111032078A (zh) | 2017-07-18 | 2020-04-17 | 血清研究所印度私人有限公司 | 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法 |
EP3749354A4 (en) * | 2018-02-05 | 2021-11-03 | Diamyd Medical AB | NEW COMPOSITION AND ITS USE |
JOP20190242A1 (ar) | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT835663E (pt) * | 1992-05-23 | 2010-01-04 | Glaxosmithkline Biolog Sa | Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios |
PL184872B1 (pl) * | 1995-06-23 | 2003-01-31 | Smithkline Beecham Biolog | Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie |
GB9611501D0 (en) * | 1996-06-03 | 1996-08-07 | Smithkline Beecham Biolog | Vaccine compositions |
-
1998
- 1998-03-25 GB GBGB9806456.1A patent/GB9806456D0/en not_active Ceased
-
1999
- 1999-03-22 TR TR2000/02737T patent/TR200002737T2/xx unknown
- 1999-03-22 JP JP2000537572A patent/JP2002507581A/ja active Pending
- 1999-03-22 DE DE69932709T patent/DE69932709T2/de not_active Expired - Lifetime
- 1999-03-22 CZ CZ20003536A patent/CZ20003536A3/cs unknown
- 1999-03-22 IL IL13799999A patent/IL137999A0/xx unknown
- 1999-03-22 AT AT99915692T patent/ATE335509T1/de not_active IP Right Cessation
- 1999-03-22 CA CA002325436A patent/CA2325436A1/en not_active Abandoned
- 1999-03-22 BR BR9909037-6A patent/BR9909037A/pt not_active IP Right Cessation
- 1999-03-22 KR KR1020007010518A patent/KR20010034630A/ko not_active Application Discontinuation
- 1999-03-22 NZ NZ506604A patent/NZ506604A/xx unknown
- 1999-03-22 CN CN99804445A patent/CN1295481A/zh active Pending
- 1999-03-22 ES ES99915692T patent/ES2270590T3/es not_active Expired - Lifetime
- 1999-03-22 HU HU0101323A patent/HUP0101323A1/hu unknown
- 1999-03-22 EP EP99915692A patent/EP1066053B8/en not_active Expired - Lifetime
- 1999-03-22 WO PCT/EP1999/001959 patent/WO1999048525A1/en active IP Right Grant
- 1999-03-22 AU AU34172/99A patent/AU735619B2/en not_active Ceased
- 1999-03-22 PL PL99343065A patent/PL343065A1/xx unknown
- 1999-03-23 AR ARP990101271A patent/AR014762A1/es not_active Application Discontinuation
- 1999-03-23 MY MYPI99001093A patent/MY133780A/en unknown
- 1999-03-25 CO CO99018131A patent/CO4820442A1/es unknown
-
2000
- 2000-09-18 ZA ZA200004956A patent/ZA200004956B/xx unknown
- 2000-09-22 NO NO20004758A patent/NO20004758L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ506604A (en) | 2003-02-28 |
AU735619B2 (en) | 2001-07-12 |
HUP0101323A1 (hu) | 2001-08-28 |
JP2002507581A (ja) | 2002-03-12 |
AR014762A1 (es) | 2001-03-28 |
WO1999048525A1 (en) | 1999-09-30 |
CA2325436A1 (en) | 1999-09-30 |
CZ20003536A3 (cs) | 2001-08-15 |
ES2270590T3 (es) | 2007-04-01 |
WO1999048525A8 (en) | 1999-11-11 |
BR9909037A (pt) | 2000-12-05 |
DE69932709T2 (de) | 2007-08-16 |
MY133780A (en) | 2007-11-30 |
NO20004758D0 (no) | 2000-09-22 |
NO20004758L (no) | 2000-11-08 |
EP1066053A1 (en) | 2001-01-10 |
ZA200004956B (en) | 2002-02-27 |
DE69932709D1 (de) | 2006-09-21 |
CO4820442A1 (es) | 1999-07-28 |
GB9806456D0 (en) | 1998-05-27 |
AU3417299A (en) | 1999-10-18 |
TR200002737T2 (tr) | 2000-12-21 |
PL343065A1 (en) | 2001-07-30 |
CN1295481A (zh) | 2001-05-16 |
ATE335509T1 (de) | 2006-09-15 |
KR20010034630A (ko) | 2001-04-25 |
EP1066053B1 (en) | 2006-08-09 |
EP1066053B8 (en) | 2006-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL137999A0 (en) | Vaccine compositions | |
IL137998A0 (en) | Combined vaccine compositions | |
HK1105581A1 (en) | Vaccine composition | |
IL148456A0 (en) | Combined vaccine compositions | |
IL138000A0 (en) | Adjuvant compositions | |
AP2000001874A0 (en) | Cellecoxib compositions | |
GB9811377D0 (en) | Compositions | |
GB9910812D0 (en) | Vaccine composition | |
GB9801870D0 (en) | Vaccine composition | |
GB2339693B (en) | Anti-mollusc compositions | |
GB9805782D0 (en) | Compositions | |
GB0016470D0 (en) | Compositions | |
GB9806810D0 (en) | Compositions | |
GB2336535B (en) | Compositions | |
GB9809347D0 (en) | Compositions | |
GB9614618D0 (en) | Vaccine compositions | |
GB9806455D0 (en) | Vaccine composition | |
GB9802879D0 (en) | Vaccine composition | |
GB9930457D0 (en) | Vaccine compositions | |
GB9930455D0 (en) | Vaccine compositions | |
GB9930461D0 (en) | Vaccine compositions | |
GB9930459D0 (en) | Vaccine compositions | |
GB9930460D0 (en) | Vaccine compositions | |
GB9930458D0 (en) | Vaccine compositions | |
GB9930456D0 (en) | Vaccine compositions |